Evidence map›Paper›PMID 36145202›Full record

ReviewNutrients2022

Unravelling the Therapeutic Potential of Nano-Delivered Functional Foods in Chronic Respiratory Diseases.

Dvya Delilaa Clarence, Keshav Raj Paudel, Bikash Manandhar, Sachin Kumar Singh, Hari Prasad Devkota, Jithendra Panneerselvam, Vivek Gupta, Nitin Chitranshi, Nitin Verma, Sonia Saad and 6 more

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 5 countries.

Dvya Delilaa ClarenceSchool of Postgraduate Studies, International Medical University (IMU), Kuala Lumpur 57000, Malaysia.
Keshav Raj PaudelCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2007, Australia.ORCID 0000-0002-3591-2080
Bikash ManandharDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0003-1276-6954
Sachin Kumar SinghAustralian Research Centre in Complementary and Integrative Medicine, Faculty of Health, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0003-3823-6572
Hari Prasad DevkotaGraduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto 862-0973, Japan.ORCID 0000-0002-0509-1621
Jithendra PanneerselvamDepartment of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia.
Vivek GuptaMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW 2109, Australia.
Nitin ChitranshiMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW 2109, Australia.
Nitin VermaChitkara School of Pharmacy, Chitkara University, Atal Nagar 174103, India.ORCID 0000-0003-2618-2749
Sonia SaadFaculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia.
Gaurav GuptaSchool of Pharmacy, Suresh Gyan Vihar University, Jaipur 302017, India.
Philip Michael HansbroCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2007, Australia.ORCID 0000-0002-4741-3035
Brian Gregory OliverWoolcock Institute of Medical Research, University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-7122-9262
Thiagarajan MadheswaranDepartment of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia.ORCID 0000-0001-5049-0659
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0002-7507-1159
Dinesh Kumar ChellappanDepartment of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia.ORCID 0000-0001-5567-6663
University of Technology Sydney · AUIMU University · MYMacquarie University · AUChitkara University · INLovely Professional University · INPokhara University · NPThe University of Sydney · AUUttaranchal University · IN

Funding

International Medical University MMM I-2021(03)
6 · The paper itself

Abstract

Chronic inflammation of the respiratory tract is one of the most concerning public health issues, as it can lead to chronic respiratory diseases (CRDs), some of which are more detrimental than others. Chronic respiratory diseases include chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis. The conventional drug therapies for the management and treatment of CRDs only address the symptoms and fail to reverse or recover the chronic-inflammation-mediated structural and functional damage of the respiratory tract. In addition, the low efficacy and adverse effects of these drugs have directed the attention of researchers towards nutraceuticals in search of potential treatment strategies that can not only ameliorate CRD symptoms but also can repair and reverse inflammatory damage. Hence, there is a growing interest toward investigating the medicinal benefits of nutraceuticals, such as rutin, curcumin, zerumbone, and others. Nutraceuticals carry many nutritional and therapeutic properties, including anti-inflammatory, antioxidant, anticancer, antidiabetic, and anti-obesity properties, and usually do not have as many adverse effects, as they are naturally sourced. Recently, the use of nanoparticles has also been increasingly studied for the nano drug delivery of these nutraceuticals. The discrete size of nanoparticles holds great potential for the level of permeability that can be achieved when transporting these nutraceutical compounds. This review is aimed to provide an understanding of the use of nutraceuticals in combination with nanoparticles against CRDs and their mechanisms involved in slowing down or reversing the progression of CRDs by inhibiting pro-inflammatory signaling pathways.

Indexed as

CurcuminPulmonary Disease, Chronic ObstructiveAnti-Inflammatory AgentsAntioxidantsFunctional FoodHumansHypoglycemic AgentsInflammationRutinAnti-Inflammatory AgentsAntioxidantsCurcuminHypoglycemic AgentsRutinfunctional foodsinflammationnanoparticlespulmonaryrespiratory diseases

Identifiers

PMID36145202
PMCPMC9503475
OpenAlexW4296360445

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.